Dilanubicel is under clinical development by Deverra Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dilanubicel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dilanubicel overview
Dilanubicel is under development for the treatment of acute myeloid leukemia, . The therapeutic candidate constitutes universal donor ex-vivo expanded cord blood progenitor and hematopoietic stem cells. It is based on ex vivo expanded umbilical cord blood platform. It is administered intravenously as an infusion. It was also under development for the treatment of blood cancer, chemotherapy-induced neutropenia in pediatrics and adults, rejection of solid organ transplant, acute radiation toxicity, acute lymphoblastic leukemia, chronic myeloid leukemia and myelodysplastic syndrome.
Deverra Therapeutics overview
Deverra Therapeutics is developing allogeneic, off-the-shelf universal donor cellular immunotherapeutic for the treatment of cancer and infectious diseases. The company is headquartered in Seattle, Washington, the US.
For a complete picture of Dilanubicel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
